IRT3 Antibody

What is IRF3 and why is it significant in immunological research?

IRF3 is a 60 kDa protein that functions as a key transcriptional regulator of type I interferon (IFN)-dependent immune responses. It plays a critical role in innate immune responses against DNA and RNA viruses. IRF3 regulates the transcription of type I IFN genes (IFN-alpha and IFN-beta) and IFN-stimulated genes (ISG) by binding to an interferon-stimulated response element (ISRE) in their promoters .

In uninfected cells, IRF3 exists in an inactive form in the cytoplasm. Following viral infection, double-stranded RNA (dsRNA), or toll-like receptor (TLR) signaling, IRF3 becomes phosphorylated by IKBKE and TBK1 kinases, inducing a conformational change that leads to dimerization, nuclear localization, and association with CREB binding protein to form dsRNA-activated factor 1 (DRAF1) . This complex activates transcription of type I IFN and ISG genes, making IRF3 a critical research target for understanding antiviral immunity.

What are the different types of IRF3 antibodies available for research applications?

IRF3 antibodies are available in several formats, including:

• Monoclonal antibodies: These offer high specificity and reproducibility, such as the rabbit recombinant monoclonal IRF3 antibody (EP2419Y) and mouse monoclonal antibodies like clone 482205 .

• Polyclonal antibodies: These recognize multiple epitopes on IRF3.

• Phospho-specific antibodies: These specifically detect phosphorylated forms of IRF3.

• Tagged antibodies: These include fluorophore-conjugated or enzyme-linked antibodies for direct detection.

The choice depends on your experimental goals, with monoclonals offering better specificity and reproducibility for most applications.

How can I determine which IRF3 antibody is best suited for my specific research question?

Selecting the appropriate IRF3 antibody requires consideration of:

• Application compatibility: Verify the antibody has been validated for your application (WB, IHC, Flow, IP, etc.) .

• Species reactivity: Ensure the antibody recognizes IRF3 from your experimental species. Many antibodies are human-specific but may cross-react with other species .

• Epitope recognition: For specific studies (e.g., phosphorylation), select antibodies targeting the relevant epitope. The EP2419Y antibody recognizes human IRF3, while clone 482205 is raised against aa 206-427 of human IRF3 .

• Published validation: Review publications citing the antibody to assess its performance in similar research contexts .

• Specific binding modes: Consider that antibodies may have different binding modes for closely related ligands, which computational models can help predict .

What are the optimal protocols for detecting IRF3 by Western blot?

For optimal Western blot detection of IRF3:

• Sample preparation:

  • Lyse cells in RIPA buffer containing protease inhibitors

  • For phospho-IRF3 detection, include phosphatase inhibitors

  • Use 20-40 μg of protein per lane

• Gel and transfer conditions:

  • Use 10% SDS-PAGE gels

  • Transfer to PVDF membrane at 100V for 1-1.5 hours

• Antibody incubation:

  • Block membrane with 5% non-fat milk or BSA

  • Dilute primary antibody as recommended (e.g., 1 μg/mL for MAB4019)

  • Incubate overnight at 4°C

  • Use appropriate HRP-conjugated secondary antibody

• Detection:

  • IRF3 typically appears at approximately 60 kDa

  • Include positive controls (e.g., Raji, Daudi, or Jurkat cell lines)

How should IRF3 antibodies be used in flow cytometry applications?

For intracellular IRF3 detection by flow cytometry:

• Cell preparation:

  • Harvest 1-5 × 10^6 cells

  • Wash with PBS containing 2% serum

• Fixation and permeabilization:

  • Fix cells with Flow Cytometry Fixation Buffer

  • Permeabilize with Flow Cytometry Permeabilization/Wash Buffer I

• Antibody staining:

  • Dilute IRF3 antibody according to manufacturer recommendations

  • Incubate for 30-60 minutes at room temperature

  • Wash and incubate with appropriate fluorophore-conjugated secondary antibody

• Controls:

  • Include isotype control (e.g., MAB0041 for mouse monoclonals)

  • Include unstained and secondary-only controls

  • Consider using cell lines with known IRF3 expression patterns (e.g., Daudi cells)

• Analysis considerations:

  • Gate on viable, single cells

  • Compare staining intensity to isotype control

  • For studies of nuclear translocation, consider imaging flow cytometry

What methodological considerations are important for IRF3 immunoprecipitation experiments?

When performing immunoprecipitation of IRF3:

• Lysis conditions:

  • Use gentle lysis buffers (e.g., NP-40 or CHAPS-based) to preserve protein-protein interactions

  • Include protease inhibitors and phosphatase inhibitors if studying phosphorylated IRF3

• Antibody selection:

  • Choose antibodies validated for IP applications (e.g., EP2419Y)

  • Ensure the antibody does not interfere with relevant protein-protein interactions

• Protocol optimization:

  • Pre-clear lysates with Protein A/G beads

  • Use 2-5 μg antibody per 500 μg of protein

  • Incubate overnight at 4°C

  • Wash extensively to reduce background

• Controls:

  • Include isotype control antibody

  • Consider using IRF3 knockout/knockdown samples as negative controls

  • Verify IP efficiency by immunoblotting a small portion of immunoprecipitated material

How can I validate the specificity of an IRF3 antibody in my experimental system?

To validate IRF3 antibody specificity:

• Knockout/knockdown controls:

  • Test the antibody on IRF3 knockout or siRNA-treated samples

  • Signal should be absent or significantly reduced

• Peptide competition:

  • Pre-incubate the antibody with excess immunizing peptide

  • Specific signal should be blocked

• Multiple antibody comparison:

  • Use antibodies recognizing different IRF3 epitopes

  • Consistent detection patterns suggest specificity

• Expected molecular weight verification:

  • IRF3 appears at approximately 60 kDa on Western blots

  • Account for post-translational modifications

• Recombinant protein control:

  • Test the antibody against purified recombinant IRF3

  • Compare signal to endogenous detection

• Bioinformatic analysis:

  • Analyze the epitope sequence for homology to other proteins

  • Computational methods can predict potential cross-reactivity

What advances in computational approaches are improving IRF3 antibody specificity?

Recent computational approaches for antibody specificity include:

• AI-based technologies:

  • Machine learning models can generate antigen-specific antibody complementarity-determining region (CDR) sequences

  • These models bypass traditional experimental approaches by mimicking natural antibody generation processes

• Biophysical modeling:

  • Models that incorporate biophysical constraints offer quantitative insights into antibody-antigen interactions

  • When coupled with experimental data, these models can predict physical features and design new antibodies with specific properties

• Binding mode identification:

  • Computational approaches can identify different binding modes associated with particular ligands

  • This enables disentangling contributions to binding from multiple epitopes in a single experiment

• High-throughput sequencing integration:

  • Combined with machine learning, high-throughput sequencing can predict properties beyond experimentally observed sequences

  • This allows inference of multiple physical properties, including specificity profiles

These computational methods are particularly valuable for designing antibodies that can discriminate between structurally and chemically similar ligands .

How can I study IRF3 phosphorylation and activation dynamics in response to viral infection?

To study IRF3 phosphorylation dynamics:

• Temporal analysis:

  • Collect samples at multiple time points after viral infection or stimulation

  • Use phospho-specific IRF3 antibodies to track activation

  • Monitor nuclear translocation using subcellular fractionation or immunofluorescence

• Pathway inhibitors:

  • Use inhibitors of TBK1/IKKε (e.g., BX-795, MRT67307) to block IRF3 phosphorylation

  • Inhibit key upstream components to delineate signaling requirements

• Quantitative approaches:

  • Use quantitative Western blotting with phospho/total IRF3 ratios

  • Implement phospho-flow cytometry for single-cell analysis

  • Consider mass spectrometry to identify specific phosphorylation sites

• Visualization techniques:

  • Use live-cell imaging with fluorescently-tagged IRF3

  • Implement proximity ligation assays to detect IRF3 interactions with signaling partners

  • Apply advanced microscopy methods like FRET to study conformational changes

• Virus-specific considerations:

  • Compare IRF3 activation patterns across different viral infections

  • Study how viral immune evasion strategies target IRF3 signaling

  • Assess IRF3 activation in the context of SARS-CoV-2 infection

What recent developments in antibody engineering are relevant for creating highly specific IRF3 antibodies?

Recent developments in antibody engineering include:

• AI-driven design:

  • AI technologies can generate de novo antigen-specific antibody sequences using germline-based templates

  • These approaches have been validated through the generation of antibodies against targets like SARS-CoV-2

• Specificity inference and design:

  • Computational models can infer binding specificity from high-throughput selection experiments

  • These models associate different binding modes with particular ligands, enabling prediction of specific variants

• Biophysics-informed modeling:

  • Models incorporating biophysical constraints help identify and disentangle multiple binding modes

  • This approach allows designing antibodies with customized specificity profiles

• Experimental-computational integration:

  • Combining phage display experiments with computational analysis enables design beyond the scope of experimentally observed sequences

  • This integration mitigates experimental artifacts and biases in selection experiments

These approaches are particularly valuable for designing antibodies that can discriminate between structurally and chemically similar epitopes, a common challenge in IRF3 research where distinguishing between phosphorylated forms is essential .

What are common issues when using IRF3 antibodies and how can they be resolved?

How can I optimize detection of IRF3 nuclear translocation?

For optimal detection of IRF3 nuclear translocation:

• Timing considerations:

  • Nuclear translocation typically occurs 1-4 hours after stimulation

  • Perform a time course to identify optimal collection points

• Subcellular fractionation approach:

  • Use commercial fractionation kits or established protocols

  • Verify fraction purity with compartment-specific markers (e.g., GAPDH for cytoplasm, Lamin B for nucleus)

  • Western blot both fractions for IRF3

• Immunofluorescence microscopy:

  • Fix cells with 4% paraformaldehyde

  • Permeabilize with 0.1-0.5% Triton X-100

  • Stain with validated IRF3 antibody and nuclear counterstain

  • Collect z-stack images for accurate colocalization assessment

  • Quantify nuclear/cytoplasmic ratio across multiple cells

• Live-cell imaging:

  • Generate cells expressing fluorescently-tagged IRF3

  • Validate that the tag doesn't interfere with translocation

  • Capture time-lapse images after stimulation

  • Use nuclear markers for colocalization analysis

• Flow cytometry approach:

  • Analyze nuclear translocation using imaging flow cytometry

  • Calculate nuclear/cytoplasmic ratios based on pixel intensity